MUC1 and lung carcinoma: In addition, the positivity rates of SFN in the DILD patients in recovery, tolerant control patients (mostly lung cancer patients), and lung cancer patients (9%, 10%, and 19%, respectively) were lower than those for KL-6 (50%, 29%, 29%, respectively) and SP-D (44%, 29%, and 26%, respectively).